Exelead

Exelead is a CDMO dedicated to the development and commercialization of therapeutics to treat life-threatening diseases. Exelead’s core technologies focus on the manufacture of sterile drug products specializing in liposomal and PEGylation formulation technologies. Exelead has development capabilities that can be utilized to improve drug delivery and drug product characterization. The Indianapolis, Indiana manufacturing facility produces proprietary parenteral pharmaceuticals for oncology and enzyme replacement treatment, as well as for the treatment of numerous infectious diseases. Our staff is a balance of: chemists, chemical engineers, microbiologists, and pharmaceutical manufacturing experts. Senior Exelead management is a mix of seasoned executives from the pharmaceutical and biotechnology industries. Exelead is a wholly owned subsidiary of Essetefin SpA (Rome, Italy) and is led by John Rigg, Vice President and General Manager. 

Share
6925 Guion Road Indianapolis, IN 46268
Tel: 317-347-2800

PharmTech News Articles

FDA issued a warning letter to Cixi Zhixin Bird Clean-Care Product Co., Ltd for violations of cGMP for finished pharmaceuticals.

The company announced an investment in a new facility in Dundalk, County Louth, Ireland.

Pharmco Laboratories received an FDA warning letter for significant violations of CGMP for finished drugs and APIs at its Florida, US facility as well as misbranding of over-the-counter (OTC) acne and sunscreen drug products.

Novo Nordisk entered a research collaboration with the University of Oxford focused on Type 2 diabetes.